Optic IconOptic Logo
|
SearchCollectionsBenchmarks

trastuzumab-emtansine

Aliases
Kadcyla

5 clinical trials

1 product

4 abstracts

4 indications

Indication
Breast Cancer
Indication
Breast Cancer (HER2-positive)
Indication
HER2-positive breast cancer
Indication
Breast Cancer Metastatic
Abstract
Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.
Org: LMU University Hospital Munich, Interdisciplinary Breast Center, Rotkreuz-Clinics Munich, West German Study Group, Ev. Hospital Bethesda,
Abstract
A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR).
Org: Miami Neuroscience Institute,
Clinical trial
A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Status: Recruiting, Estimated PCD: 2023-06-29
Clinical trial
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Status: Active (not recruiting), Estimated PCD: 2015-02-01
Clinical trial
A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study:
Status: Not yet recruiting, Estimated PCD: 2030-03-30
Abstract
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Org: Université de Montréal, McGill University Health Center, Department of Medical Oncology, Institut du Cancer de Montpellier, Institut de Génomique fonctionnelle, CNRS, University of MontpellierOncology, Institute of Oncology Ljubljana,
Abstract
Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC).
Org: Memorial Sloan Kettering Cancer Center, Resolution Bioscience, Agilent,
Product
Trastuzumab Emtansine